Maple Capital Management Inc. Purchases 1,748 Shares of Johnson & Johnson $JNJ

Key Points

• Maple Capital Management Inc. increased its stake in Johnson & Johnson by 1.1%, acquiring an additional 1,748 shares to hold a total of 167,981 shares, worth approximately $27.86 million.
• Several institutional investors, including Highline Wealth Partners LLC and Harvest Fund Management Co. Ltd, have also increased or initiated positions in Johnson & Johnson during the first quarter.
• Analysts have raised their price targets for Johnson & Johnson, with Citigroup setting a target of $200.00, reflecting a generally positive outlook for the stock which has a current consensus rating of "Moderate Buy."

Maple Capital Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,981 shares of the company's stock after acquiring an additional 1,748 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Maple Capital Management Inc.'s holdings, making the stock its 19th largest position. Maple Capital Management Inc.'s holdings in Johnson & Johnson were worth $27,858,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Morgan Stanley raised their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. UBS Group raised their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Citigroup raised their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.5%

NYSE JNJ opened at $178.40 on Friday. The stock has a fifty day moving average of $170.36 and a 200-day moving average of $161.22. The stock has a market capitalization of $429.65 billion, a P/E ratio of 19.08, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.